Abstract:
Pyridazinone is oxo-pyridazine derivative compound that has broad bioactivity, such as an
analgesic, anti-inflammatory, antidiabetic, antihypertensive and anticancer. Pyridazinone 6-
(3-bromophenyl)-2-(phenylsulfonyl)pyridazine-3(2H)-one was synthesized from 6-(3-
bromophenyl)pyridazine-3(2H)-one through a Claisent-Schmidt condensation reaction
between 3-bromo acetophenone and glyoxylic acid then a cyclization reaction occurs with
hydrazine hydrate. The pyridazinone compound formed is substituted with the
benzensulfonyl chloride. The structure of the synthesized compound was confirmed by
characterization using UV, FTIR, 1H-NMR and HRMS spectroscopy. Pyridazinone
compounds were tested for their antidiabetic activity through molecular docking and in
vitro studies. A molecular docking study was performed on the crystal structure of human
lysosomal α-glucosidase (PDB ID: 5NN5) and compared with acarbose as a positive
control. The activity of the PDZ-3Br-BZS compound was less good activity in inhibiting
the α-glucosidase enzyme, which is 2.481% and confirmed by molecular docking studies
that it only has one hydrogen bond interaction in common with acarbose, that is with the
amino acid Asp 616 and a large bond free energy of -10 ,9567 kcal/mol compared to
acarbose which is -18,2395 kcal/mol.
